Financing round brings five new investors to Atonarp, including Japan Post Investment Corporation and SBI Investment Co., Ltd.- Series C was oversubscribed as investor demand was driven by the company's accelerating development progress of disruptive healthcare diagnostics platform.
Funding will be used primarily to support Atonarp's product prototyping and commercialization in 2020 and beyond, as well as build on and reinforce the company's technology platforms.TOKYO, Aug. 26, 2019 /PRNewswire/ -- Atonarp, a hi-tech molecular diagnostics company, today announced that it has raised $33 million in an oversubscribed Series C funding round.